It is unparalleled how Babu's™ revolutionary treatment method for COVID-19 is gaining attention. With the pandemic taking its greater and greater toll every day, and with the recent suppositions of another wave breaking through this fall, an effective and safe treatment is much needed. Babu™ is here to help and we are proud of our CEO, Steve Liebich, who does everything in his power to secure people's lives. His actions have been observed by yet another TV station in Poland, his original country, which decided to ask him questions on Babu's™ treatment method, Steve's thoughts of the current global situation, and the future perspectives.
Babu's™ founder and CEO, Steve Liebich, has been recognized as the inventor of a revolutionary drug for COVID-19 and asked to give an interview for the biggest Polish TV news station, TVN
For more information, visit the website!
Babu™ is proud to announce that we have officially started a collaborative project with Boston University which will assist with our project of developing the revolutionary therapeutic and prophylactic drug (BABU-ONE™) for COVID-19. The NEIDL provides ample biosafety level 3 and 4 laboratories required for the work with infectious SARS-CoV-2. Together, we will work towards providing the world with our drug prototype and secure the lives of thousands of people.
We have filed a patent to the U.S. Patent and Trademark Office for our treatment technology. Since we are officially on the path towards the drug (BABU-ONE™ ) prototype development, we are one step closer from our common success!
Babu's™ CEO & Founder, Steve Liebich, has released today (April 4, 2020) the company's first own-developed (in silico!) cure, not just any cure, but a potential treatment proposal for COVID-19. Working relentlessly and without any break, Steve decided to participate in this cooperative fight against one of the deadliest enemies that our civilization has encountered since the outbreak of the Spanish flu. Only a proposal, this putative treatment can also function as a specific prophylactic tool securing the safety of the most susceptible and the ones put int the highest danger. The treatment is based on oligonucleotide aptamers which have been locked out by big pharmaceutical and biotech companies because of the highly commercialized and money-making antibodies business. This is only the beginning and only time will tell what may happen next. The research proposal is available below.
Difficult times have knocked at our doors, but we will survive this and we will defeat SARS-CoV2 because we have the resources. However, the more people will involve in the current situation, the quicker we will be able to respond and react. Babu™ has officially announced opening its scientific resources to any research facility that would require our manpower, expertise, and marketing tools. Even though our scientific resources in the fields of immunology and microbiology are limited, we will give whatever we can give and we will share whatever we can share. We are kindly asking others to follow the footsteps of all biotech, IT, PR, marketing, healthcare, and other companies that already have done it as well. Let's get through it TOGETHER!
With sincere wishes of health,
We are extremely proud that AGT and our Institute have come closer to establishing a tight and immensely powerful partnership for the next several years! Where creativty cures, people will live longer, healthier, and better. This is the promise that both companies make.
Watch a video recorded by AGT speaking of the company's fine biotech advancements and how their progress meets the Mission and Vision of Babu™.
Babu™ is proud to announce its first promotional video, where the Institute's founder and CEO, Steve Liebich, and the CFO, Patrick Hurley, present the main ideas that build Babu™ and explain why it is destined for grandeur. Transparency and vivid dialogue with other people is what makes things turn around - Babu™ wants to talk about the future, but most importantly - Babu™ wants to become the future!
Babu™ is proud to officially announce its investment and ongoing partnership with the American Gene Technologies (AGT) – one of the world’s finest gene therapy biotechnology companies. Using a “proprietary gene delivery platform to rapidly develop patented gene and cell therapies”, AGT has created a working platform of genetic tools and components to cure HIV, phenylketonuria (PKU), and liver cancer. With their revolutionary gene therapy platform, the potential to save millions of lives from once incurable diseases becomes unlocked. This is the future of our decade that Babu™ brings to your home. Together we will bring you longer, healthier, and better lives!
To learn more on how Babu™ and AGT envision their future together you shall read this statement of future partnership.
Telocyte’s founder and president, Michael Fossel, has recently published a highly influential paper in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association which was called by the editors as “the most important article we have ever published.” The paper already has had more than 300 requests for reprints. This article not only explains why telomere- based theories of ageing are the future in modern biogerontology, but also delivers the most up- to-date characterization of pathophysiology of Alzheimer’s disease (AD). Telocyte’s gene therapy developed for AD, and supported by Babu™, can be better understood with the rationale within Dr. Fossel’s article that can be found here.